

Evidence-based Guidelines for the Management of Exocrine Pancreatic Insufficiency After Pancreatic Surgery

Luis Sabater, MD, PhD,* Fabio Ausania, MD, PhD,† Olaf J. Bakker, MD, PhD,‡ Jaime Boadas, MD, PhD,§ J. Enrique Domínguez-Muñoz, MD, PhD,¶ Massimo Falconi, MD, PhD,|| Laureano Fernández-Cruz, MD, PhD,** Luca Frulloni, MD, PhD,†† Víctor González-Sánchez, MD, PhD,‡‡ José Lariño-Noia, MD, PhD,¶¶ Björn Lindkvist, MD, PhD,§§ Félix Lluís, MD, PhD,¶¶ Francisco Morera-Ocón, MD, PhD,* Elena Martín-Pérez, MD, PhD,|||| Carlos Marra-López, MD, PhD,*** Ángel Moya-Herraiz, MD, PhD,††† John P. Neoptolemos, MD, PhD,††† Isabel Pascual, MD, PhD,§§§ Ángeles Pérez-Aisa, MD, PhD,¶¶¶ Raffaele Pezilli, MD, PhD,||||| José M. Ramia, MD, PhD,**** Belinda Sánchez, MD, PhD,†††† Xavier Molero, MD, PhD,†††† Inmaculada Ruiz-Montesinos, MD, PhD,§§§§ Eva C. Vaquero, MD, PhD,¶¶¶¶ and Enrique de-Madaria, MD, PhD,||||||

Objective: To provide evidence-based recommendations for the management of exocrine pancreatic insufficiency (EPI) after pancreatic surgery.

Background: EPI is a common complication after pancreatic surgery but there is certain confusion about its frequency, optimal methods of diagnosis, and when and how to treat these patients.

Methods: Eighteen multidisciplinary reviewers performed a systematic review on 10 predefined questions following the GRADE methodology. Six external expert referees reviewed the retrieved information. Members

from Spanish Association of Pancreatology were invited to suggest modifications and voted for the quantification of agreement.

Results: These guidelines analyze the definition of EPI after pancreatic surgery, (one question), its frequency after specific techniques and underlying disease (four questions), its clinical consequences (one question), diagnosis (one question), when and how to treat postsurgical EPI (two questions) and its impact on the quality of life (one question). Eleven statements answering those 10 questions were provided: one (9.1%) was rated as a strong recommendation according to GRADE, three (27.3%) as moderate and seven (63.6%) as weak. All statements had strong agreement.

From the *Department of Surgery, Hospital Clínico, University of Valencia, Valencia, Spain; †Department of Surgery, Complejo Hospitalario Universitario de Vigo, Vigo, Spain; ‡Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands; §Department of Gastroenterology, Consorci Sanitari de Terrassa, Terrassa, Spain; ¶Department of Gastroenterology, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain; ||Department of Surgery, Università Vita e Salute, Ospedale San Raffaele IRCCS, Milano, Italy; **Department of Surgery, Institut de Malalties Digestives i Metabòliques, Hospital Clínic, IDIBAPS, Barcelona, Spain; ††Department of Medicine, Pancreas Center, University of Verona, Verona, Italy; ‡‡Department of Endocrinology and Nutrition, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante, Alicante, Spain.; §§Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; ¶¶Department of Surgery, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante, Alicante, Spain.; ||||Department of Surgery, Hospital Universitario de La Princesa, Madrid, Spain; ***Department of Gastroenterology, Complejo Hospitalario de Navarra, Pamplona, Spain; †††Unidad de Cirugía Hepatobilio-pancreática y Trasplante, Hospital Universitari i Politecnec. La Fe, Valencia, Spain; ††††NIHR Pancreas Biomedical Research Unit, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK; §§§Department of Gastroenterology, Hospital Clínico, University of Valencia, Valencia, Spain; ¶¶¶Unit of Digestive Disease, Agencia Sanitaria Costa del Sol, Marbella, Málaga; |||||Department Digestive System, Sant'Orsola-Malpighi Hospital, Bologna, Italy; ****Department of Surgery, Hospital Universitario de Guadalajara, Guadalajara, Spain; †††††Department of HPB Surgery and Liver Transplantation, Hospital Carlos Haya, Malaga, Spain; †††††Exocrine Pancreas Research Unit, Hospital Universitari Vall d'Hebron, Institut de Recerca, Universitat Autònoma de Barcelona, CIBEREHD, Barcelona, Spain; §§§§Department of Digestive Surgery- Division of HBP Surgery, Hospital Universitario Donostia, San Sebastián, Spain; ¶¶¶¶Department of Gastroenterology, Institut de Malalties Digestives i Metabòliques, Hospital Clínic, IDIBAPS, CiberEHD, Barcelona, Spain; and ||||||Department of Gastroenterology, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante, Alicante, Spain.

Author's contribution:

L.S. and E. de-M have directed the project, proposed and coordinated the authors, risen the initial questions and developed the methodology, as well as written the manuscript. F.A., J.B., J.E.D-M., L.F-C., V.G-S., J.L-N., F.L.L., F.M-O., E.M-P., C.M-L., A.M-H., I.P., A.P-A., J.M.R., B.S., X.M., I.R-M., E.C.V. are primary reviewers and carried out the systematic review as well as contributing to

reviewing the manuscript. O.J.B., M.F., L.F., B.L., J.P.N., and R.P. contributed as external expert referees, and reviewed the manuscript adding comments or ideas to improve the quality of the manuscript.

L. S. and E. de-M. contributed equally to this work.

Reprints will not be available from the author(s).

Funding: All the authors included in this article declare to have received no funding for this work from any of the following organizations: National Institutes of Health (NIH); Wellcome Trust; Howard Hughes Medical Institute (HHMI); and other(s).

All the authors declare also that neither they nor their institutions at any time have received payment or support in kind for any aspect of the submitted work (including grants, data monitoring board, study design, manuscript preparation, statistical analysis, and so on).

Disclosure: All the authors declare that neither they nor their institutions at any time have received payment or support in kind for any aspect of the submitted work (including grants, data monitoring board, study design, manuscript preparation, statistical analysis, and so on). L. S. has participated in the development of teaching resources and educational programs for Mylan and Abbott Laboratories.

F. A., J. L-N., E. M-P. and I. P. have participated in the development of educational programs for Mylan and Abbott Laboratories. J. E. D-M. has acted as advisor, speaker and has received unrestricted research grants from Mylan and Abbott Laboratories. B. L. has received speaker's honoraria from Abbott. Á. P-A. has received a grant and speaker's honoraria from Mylan. E. de-M. has received a grant from Abbott and has assessed Mylan in the development and performance of clinical research in exocrine pancreatic insufficiency. L. S. and E. de-M. contributed equally to this work.

J. P. N. has acted as consultant for Boehringer Ingelheim Pharma GmbH & Co. KG, Novartis Pharma AG, KAEL GemVax, Astellas; received grants from Taiho Pharma (Japan), KAEL GemVax (Korea), AstraZeneca; lectures for Amgen and Mylan; meeting expenses from NUCANA and research award from Pharma Nord; funding research from Cancer Research UK, Pancreatic Cancer Research Fund and North West Cancer Research.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.annalsofsurgery.com).

Reprints: Enrique de-Madaria, MD, PhD, Department of Gastroenterology, Servicio de Aparato Digestivo, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL—Fundación FISABIO). C/ Pintor Baeza sin número. 03010, Alicante, Spain. E-mail: madaria@hotmail.com.

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.

ISSN: 0003-4932/16/26406-0949

DOI: 10.1097/SLA.0000000000001732

Conclusions: EPI is a frequent but under-recognized complication of pancreatic surgery. These guidelines provide evidence-based recommendations for the definition, diagnosis, and management of EPI after pancreatic surgery.

Keywords: pancreatic exocrine insufficiency, surgery, pancreas, pancreatic, diagnosis, treatment, guidelines

(*Ann Surg* 2016;264:949–958)

Exocrine pancreatic insufficiency (EPI) is a common complication after pancreatic surgery. Depending on the underlying disease, type of surgical procedure, extent of pancreatic resection, and anatomical reconstruction, EPI may vary in frequency and severity. Despite the large amount of information dealing with general post-operative complications, there is a lack of well-designed studies investigating EPI. This has led to a certain degree of confusion about the frequency of EPI after surgery, its optimal methods of diagnosis and when and how to treat these patients. The aim of these guidelines is to provide evidence-based recommendations for the diagnosis and treatment of EPI after pancreatic surgery.

METHODS

The Spanish Association of Pancreatology (AESPANC) led the initiative and chose two coordinators (E. de-M. and L. S.) who developed the methodology. Eighteen Spanish primary reviewers were chosen, based on their expertise in pancreatic surgery, clinical pancreatology or nutrition (nine surgeons, eight gastroenterologists, and one endocrinologist). A group of external expert referees, composed by three pancreatic surgeons and three gastroenterologists, were invited to participate in the project. These referees were selected among internationally renowned researchers in pancreatology. A draft of the questions to be addressed was proposed by the coordinators and discussed by the whole team (via e-mail) finally resulting in 10 questions.

The coordinators assigned each question to two or three primary reviewers based on their expertise. A working plan for the systematic review was provided, inspired by the IAP/APA evidence-based guidelines for the management of acute pancreatitis.¹ All reviewers were asked to take a GRADE system tutorial (link on UpToDate: <http://www.uptodate.com/home/grading-tutorial>).

The systematic research for suitable articles was performed in the PubMed and Cochrane databases without language restriction. The authors were provided with a search algorithm for each question (see supplementary material 1, <http://links.lww.com/SLA/B4>). In addition, studies from the citations of the reviewed articles could also be included.

The inclusion criteria to select the articles were as follows: observational studies, clinical trials, and meta-analysis/systematic reviews relevant to the specific question. Studies published only as abstracts were excluded.

The primary reviewers were asked to write a report including:

1. A table with a structured summary of the included studies (authors, journal, date of publication, design, population, definition of outcome variable, results, and comments).
2. An evidence-based statement to the study question.
3. The strength of the recommendation (1 = strong, 2 = weak) and quality of evidence (A = high, B = moderate, C = low) according to the GRADE guidelines as adapted for “UpToDate” (Table 1).
4. Remarks: a brief (up to 750 words) commentary explaining current evidence to support the recommendation.

The external expert referees were asked to review the report of the primary reviewers; their task was to check that:

1. There was no relevant study missing.
2. Included studies met the eligible criteria.

3. There was no mistake in the report of the included studies.
4. The strength of recommendation was adequate according to the retrieved evidence.

With the retrieved information by primary reviewers and external expert referees, the coordinators wrote a first draft of the manuscript. This draft was reviewed by the whole team and afterwards shared electronically with the members of AESPANC. The members of AESPANC voted on a five-point Likert scale (A: “definitely yes”, B: “probably yes”, C: “no specific recommendation”, D: “probably no”, and E: “definitely no”) on the statements and their GRADE score. It was defined that “strong agreement” would require at least 70% of votes to be either “definitely yes” or “probably yes”. The members of AESPANC also had the possibility of making suggestions in open text for every question, aiming not to modify the statement but to include clinically relevant remarks.

With the feedback from AESPANC members, the coordinators wrote the second draft of the article that was shared again with the primary reviewers and with the external expert referees for suggestions and final approval.

RESULTS

Question 1

What Is the Definition of EPI After Pancreatic Surgery?

Statement. EPI after pancreatic surgery is defined as the condition in which the amount of secreted pancreatic enzymes is not enough to maintain a normal digestion because of modifications of gastrointestinal anatomy together with functional changes caused by underlying pancreatic disease, extent of pancreatic tissue removed, reduced postprandial stimulation, and asynchrony between gastric emptying of nutrients and pancreatic enzyme secretion.

Strength of the Recommendation and Quality of Evidence: 1C. Strong Agreement (A: 87.5%; B: 12.5%)

Remarks. There is no widely accepted consensus definition of EPI, and there are no studies aiming to validate different EPI definitions with outcome variables after pancreatic surgery. Published studies addressing EPI after surgery have different definitions according to the different pancreatic function test (PFT) used in each particular study. From a pragmatic point of view, EPI may be defined as the situation in which the disturbance of pancreatic function is associated with the inability of the pancreas to perform normal digestion.² Thus, an abnormally high fecal fat excretion (FFE) (>7 g/day) or a Coefficient of Fat Absorption (CFA) <93% (equivalent to a FFE >7 g/day under a diet containing 100 g of fat/day) is characteristically indicative of EPI in clinical practice^{2–4} and should be considered as a gold standard. EPI after surgery may be secondary to a reduced pancreatic secretion caused by the underlying pancreatic disease,^{3,5} extent of pancreatic resection,⁶ reduced postprandial stimulation,^{7,8} and gastrointestinal anatomical changes leading to an asynchrony between gastric emptying of nutrients and enzyme secretion.⁹

Question 2

What Is the Frequency of EPI in Patients With Acute Pancreatitis After Pancreatic Necrosectomy?

Statement. The frequency of EPI in patients with acute pancreatitis after necrosectomy is variable because of significant heterogeneity in the design and population of available studies addressing this issue. Pancreatic function tends to improve and consequently frequency of EPI diminishes over time after necrosectomy. About a quarter of patients with acute necrotizing pancreatitis present EPI after pancreatic necrosectomy.

TABLE 1. Grading Recommendations

Grade of Recommendation	Clarity of Risk/Benefit	Quality of Supporting Evidence	Implications
1A. Strong recommendation, high quality evidence	Benefits clearly outweigh risk and burdens, or vice versa	Consistent evidence from well performed randomized, controlled trials or overwhelming evidence of some other form. Further research is unlikely to change our confidence in the estimate of benefit and risk	Strong recommendations, can apply to most patients in most circumstances without reservation. Clinicians should follow a strong recommendation unless a clear and compelling rationale for an alternative approach is present
1B. Strong recommendation, moderate quality evidence	Benefits clearly outweigh risk and burdens, or vice versa	Evidence from randomized, controlled trials with important limitations (inconsistent results, methodologic flaws, indirect or imprecise), or very strong evidence of some other research design. Further research (if performed) is likely to have an impact on our confidence in the estimate of benefit and risk and may change the estimate	Strong recommendation and applies to most patients. Clinicians should follow a strong recommendation unless a clear and compelling rationale for an alternative approach is present
1C. Strong recommendation, low quality evidence	Benefits appear to outweigh risk and burdens, or vice versa.	Evidence from observational studies, unsystematic clinical experience, or from randomized, controlled trials with serious flaws. Any estimate of effect is uncertain	Strong recommendation, and applies to most patients. Some of the evidence base supporting the recommendation is, however, of low quality
2A. Weak recommendation, high quality evidence	Benefits closely balanced with risks and burdens.	Consistent evidence from well performed randomized, controlled trials or overwhelming evidence of some other form. Further research is unlikely to change our confidence in the estimate of benefit and risk	Weak recommendation, best action may differ depending on circumstances or patients or societal values
2B. Weak recommendation, moderate quality evidence	Benefits closely balanced with risks and burdens, some uncertainly in the estimates of benefits, risks, and burdens.=	Evidence from randomized, controlled trials with important limitations (inconsistent results, methodologic flaws, indirect or imprecise), or very strong evidence of some other research design. Further research (if performed) is likely to have an impact on our confidence in the estimate of benefit and risk and may change the estimate	Weak recommendation, alternative approaches likely to be better for some patients under some circumstances
2C. Weak recommendation, low quality evidence	Uncertainty in the estimates of benefits, risks, and burdens; benefits may be closely balanced with risks and burdens	Evidence from observational studies, unsystematic clinical experience, or from randomized, controlled trials with serious flaws. Any estimate of effect is uncertain	Very weak recommendation; other alternatives may be equally reasonable

From: <http://www.uptodate.com/home/grading-guide>.

Strength of the Recommendation and Quality of Evidence: 1C Strong Agreement (A: 45%; B: 55%)

Remarks. There is a great heterogeneity in the design of studies addressing EPI after pancreatic necrosectomy. Some studies used FFE to assess pancreatic function and define EPI as FFE >7 g/24 h. Gupta et al¹⁰ reported increased FFE in six out of 21 patients (28.6 %) at least 6 months after necrosectomy. Sabater et al¹¹ compared exocrine pancreatic function in patients with severe biliary AP with and without necrosectomy. Pancreatic function was assessed by FFE, fecal chymotrypsin and secretin-cerulein test (SCT), 12 months after AP. Seven out of 12 patients with necrosectomy (58.3 %) had abnormal PFT, with steatorrhea in three patients (25 %). Reddy et al¹² reported increased FFE in eight out of 10 (80 %) patients with necrosectomy, but no patient had symptoms of steatorrhea or EPI. Tsiotos et al¹³ and Bavare et al¹⁴ defined EPI with FFE, but it was only performed in patients with significant changes in bowel habit; thus, the prevalence of EPI could be underestimated.

Angelini et al¹⁵ reported EPI (evaluated with SCT) in eight out of 20 patients with necrosectomy (40 %) at 12 to 36 months and in 6.6

% at 36 to 48 months after the onset of disease. Seligson et al¹⁶ detected EPI in 7/10 (70%) patients with Lundh Test.

Other studies are hampered by important biases: the presence of acute and chronic pancreatitis¹⁷ or the inclusion of nonoperated patients.¹⁸ Finally, in some studies, EPI was reported on the basis of need for pancreatic enzymes or clinical symptoms of steatorrhea, with figures between 23¹⁹ and 25%,²⁰ respectively. In this regard, it is noteworthy to highlight the results of the PANTHER trial from the Dutch Pancreatitis Study group, in which the minimally invasive step-up approach was significantly associated with a lower need for pancreatic enzymes than in primary open necrosectomy (7 vs 33%).²¹

Question 3

What Is the Frequency of EPI in Patients with Chronic Pancreatitis After Pancreatic Surgery?

Statement. The incidence of EPI in patients with chronic pancreatitis after derivative surgery or hybrid procedures is the

following: (i) after Partington-Rochelle procedure there are clinical steatorrhea and/or other clinical symptoms in 0 to 32% of patients and altered PFT in 80%; (ii) after Frey procedure there are clinical steatorrhea and/or other clinical symptoms in 33% of patients and altered PFT in 86%; (iii) after duodenum preserving pancreatic head resection (DPPHR) there are clinical steatorrhea and/or other clinical symptoms in 26 to 34% of patients and altered PFT in more than 80% of patients.

The incidence of EPI after pancreatoduodenectomy (PD) for chronic pancreatitis is high, within the range of 35 to 100%, most of the studies showing >60%. The incidence of EPI after distal pancreatectomy (DP) for chronic pancreatitis seems to be lower, ranging from 27.5 to 63%.

As there is a high prevalence of EPI in chronic pancreatitis patients, and few studies evaluate EPI before pancreatic surgery, the specific contribution of the surgical procedure to EPI is difficult to quantify.

Strength of the Recommendation and Quality of Evidence: 1C Strong Agreement (A: 52.5%; B: 45%; C: 2.5%)

Remarks. The studies addressing EPI in patients with chronic pancreatitis after derivative surgery or hybrid procedures can be divided into five groups: articles comparing Partington-Rochelle versus PD^{22–25}; articles comparing Frey versus PD^{26–28}; articles comparing DPPHR versus PD^{29–36}; articles comparing DPPHR versus Frey procedure,^{37,38} and miscellaneous retrospective series.^{39–41} According to these studies, (i) after Partington-Rochelle procedure there are clinical steatorrhea and/or other clinical symptoms in 0 to 32% of patients and altered PFT in 80%; (ii) after Frey procedure there are clinical steatorrhea and/or other clinical symptoms in 33% of patients and altered PFT in 86%; and (iii) after duodenum preserving pancreatic head resection (DPPHR) there are clinical steatorrhea and/or other clinical symptoms in 26 to 34% of patients and altered PFT in more than 80% of patients.

Regarding the frequency of EPI in patients with chronic pancreatitis after resectional procedures (PD, DP), four prospective RCT^{28,30,31,34} (two of them with long-term follow-up), two prospective nonrandomized studies,^{26,29} two meta-analyses,^{32,35} and 10 retrospective studies^{22–24,27,33,40,42–45} were included. The incidence of EPI after PD operation ranged from 35 to 100%. However, some concerns can be raised as to the quality of these findings. First, EPI was not the primary outcome in the majority of these studies, which were mainly designed to compare different surgical techniques. Furthermore, definition of EPI was not homogeneous and it seems that clinical definition (expressed by questionnaire or need for pancreatic enzymes) detected a generally lower number of patients with EPI when compared with PFT. Second, in most nonrandomized studies, Whipple's operation was performed when pancreatic cancer was suspected or pancreatic duct was not dilated, causing an important selection bias. Finally, preoperative assessment of EPI was scarcely performed and high variability was reported among studies. Except for one study,⁴² surgery always increased the incidence of EPI. The two meta-analyses^{32,35} do not report any definition of EPI, hence making interpretation difficult. The only study that seems to avoid the previously mentioned biases is Izbicki's RCT,⁴⁶ whose long-term results have been reported by Bachmann et al.²⁸ This study shows that the incidence of EPI is 93% with a 15-year follow up and thus this value should be taken into account when predicting the occurrence of EPI following PD for chronic pancreatitis. An important consideration regarding maldigestion after this operation is that, in addition to the reduction of pancreatic tissue,⁶ PD alters the physiological mechanisms that regulate gastric emptying,

stimulation of biliopancreatic secretions and mixing of the nutrient particles with pancreatic enzymes because of the removal of structures that are necessary for normal digestion.^{9,47,48} This procedure leads to an asynchrony between the gastric emptying of nutrients and biliopancreatic secretion for the following reasons: (i) the loss of antropfundic and duodenofundic reflexes that hinders the accommodation of nutrients in the gastric cavity; (ii) the absence of neurally mediated pancreatic stimulation; (iii) loss of food-grinding capacity that results in large nutrient particles that cannot be adequately mixed with biliary and pancreatic secretions and are therefore difficult to be absorbed by the intestine; and (iv) the resection of duodenum which avoids the release of cholecystokinin^{7,8} and consequently there is a reduction of postprandial hormonal pancreatic stimulation.

Regarding DP, the incidence of EPI ranged from 27.5 to 63%. As mentioned before, the definition of EPI and the scarce preoperative assessment of pancreatic function can be considered strong biases.

Question 4

What Is the Frequency of EPI in Patients With Pancreatic Tumors After Resection (PD, DP)?

Statement. The incidence of EPI after PD for pancreatic tumors is high, especially in patients undergoing PD caused by malignancy, with a range of 64 and 100%. The incidence of EPI after DP is lower than after PD, within a range of 0 to 42%.

Strength of the Recommendation and Quality of Evidence: 1C Strong Agreement (A: 67.5%; B: 32.5%)

Remarks. Information regarding the incidence of EPI in patients with pancreatic tumors after resection is limited and there is a lack of well-designed studies. Most available studies are retrospective and cross-sectional, limited by small sample size and single-institution designs. They also include a heterogeneous patient population with malignant and benign diseases. They include different types of surgery: PD, DP, and atypical resections. In addition, most of the reports include patients with and without chronic pancreatitis, and have used different methods to assess the pancreatic exocrine function. As mentioned before, maldigestion after PD has a complex pathophysiology that involves other factors besides the removal of pancreatic tissue (see questions 1 and 3).

Twenty-two studies have described the impairment of exocrine function after pancreatic head resection;^{4–6,49–67} 14 studies included only patients who underwent PD,^{5,52,54,56–62,64–67} seven studies included both PD and DP^{4,6,49,50,53,55,63} (central or total pancreatectomy in three of them),^{50,53,55} and one study included PD and total pancreatectomy.⁵¹ Fourteen studies included a heterogeneous patient population with malignant and benign diseases,^{6,50–54,56–60,62–64} five studies included only patients with malignant disease,^{4,5,49,61,66} and one study covered only benign tumors.⁵⁵ There was also one meta-analysis.⁶⁸

Among the studies, seven different methods for the assessment of EPI were applied (Table 2). As seen in this table, depending on the method used to evaluate exocrine pancreatic function, results vary considerably.

EPI rates varied widely from 24 to 100%. When only considering patients who underwent PD for malignant disease, EPI was present in 64 to 100%.^{4,5,49,61} Five studies^{49,55,58,63,64} have evaluated the preoperative and postoperative exocrine function. In the study by Sikkens et al.,⁴⁹ EPI was present in 44.8% at the time of diagnosis of pancreatic cancer increasing to 89% at the end of follow up. However, follow up was limited to 6 months, the long-term course was not evaluated, and the study covered two types of surgery (DP and PD). In

TABLE 2. Variability in Exocrine Pancreatic Insufficiency After pancreatoduodenectomy According to the Different Methods Used for Measuring EPI

Method	EPI %	References
Coefficient of fat absorption	55	4
Fecal fat excretion	87.5, 94	51, 62
13C-labelled mixed triglyceride breath test	64, 62.3, 51	6, 54, 67
Urinary PABA excretion rate	33, 75	64, 65
Fecal elastase 1	91, 59, 87.5, 50, 74.5, 100, 94.5, 97.5, 100	5, 49–51, 57, 58, 60–62
Fecal chymotrypsin levels	24, 33	53, 55
Clinical steatorrhea	52.8, 52.4, 42, 64.5	52, 56, 59, 66

EPI indicates exocrine pancreatic insufficiency; PABA, para-aminobenzoic acid.

the series by Falconi et al⁵⁵ including 51 PD for benign tumors with normal preoperative pancreatic exocrine function, EPI was observed in 33% at the end of follow up. Matsumoto and Traverso⁵⁸ reported a preoperative EPI rate of 33% (68% in pancreatic adenocarcinoma, and 46% in malignant vs 21% in benign disease), increasing to 73% after 1 year. In the study of Sato et al,⁶³ the frequency of EPI increased from 44% in the preoperative period to 81% after pancreatic resection, but follow up was limited to only 2 months. One study⁶⁴ suggested that postoperative impairment of pancreatic exocrine function was transient and reversible. EPI was present in 46% preoperatively, rose to 75% at the short-term (within 2 months), and then decreased to 33% after 12 months, but this observation was based on data from only nine patients. Furthermore, the study included a heterogeneous group of patients with malignant and benign diseases.

Regarding DP, the incidence of EPI varied from 0 to 42% depending on the method used to assess pancreatic exocrine function. Similar biases can be observed in the studies evaluating this procedure as in PD and in fact most of the studies include both PD and DP.^{4,6,49,50,53,55,63} One study⁶⁹ showed that most patients who underwent DP for benign or malignant pancreatic disease did not experience permanent postoperative EPI: all patients had normal exocrine function after DP or extended DP at 24 months after surgery and in the few cases where lower values were observed at 3 and 12 months after DP, the effect was transient. In the study by Falconi et al⁵⁵ including 50 left pancreatectomies for benign tumors with normal preoperative fecal chymotrypsin levels, 18% presented EPI at the end of follow up. Sato et al⁶³ studied 12 patients who underwent DP for benign or malignant tumors of the pancreas and did not observe a significant decline in exocrine function after DP. Finally the meta-analysis by Xu et al,⁶⁸ showed an EPI rate of 10.8% in DP.

Question 5

What Is the Frequency of EPI in Patients With Central Pancreatectomy? Statement

Central pancreatectomy is a conservative resectional procedure that is associated with low rates of EPI, approximately 10%.

Strength of the Recommendation and Quality of Evidence: 1C Strong Agreement (A: 62.5%; B: 35%; D: 2.5%)

Remarks. Studies addressing EPI in central pancreatectomy (CeP) have two important shortcomings: (i) with two exceptions^{70,71}

the studies addressing EPI in CeP are retrospective and (ii) most studies do not report PFT in patients with CeP and most reports of EPI are based on clinical suspicion of steatorrhea and/or need for enzymes. Furthermore, the only two prospective studies^{70,71} did not perform PFT on patients with CeP.

Two studies reported FFE after CeP in patients with benign/low grade pancreatic tumors resulting in only one among 28 (3.6%) patients with EPI.^{72,73} In seven studies other PFT were performed after CeP^{53,55,74–78} reporting a range of EPI between 0^{55,74,76,77} and 21%.⁷⁸ Studies reporting clinical EPI (steatorrhea and/or weight loss and/or need for enzymes) describe a range between 0^{79–88} and 43%.⁷¹ In a systematic review published in 2013, which included 21 studies, EPI (diagnosed either clinically or by means of diverse PFT) was noted in 9.9% of the patients.⁸⁹

Question 6

What Are the Clinical Consequences of EPI?

Statement. EPI after pancreatic surgery may be subclinical or associated with symptoms secondary to the presence of undigested food in the intestinal lumen (fatty diarrhea, flatulence, and dyspeptic symptoms) and/or those associated with the loss of nutrients (weight loss, fat-soluble vitamin deficit).

Strength of the Recommendation and Quality of Evidence: 1C Strong Agreement (A: 77.5%; B: 17.5%; C: 2.5%; D: 2.5%)

Remarks. EPI after pancreatic surgery is associated with abnormal total energy absorption because of decreased digestion of fat, proteins, and carbohydrates.⁹⁰ EPI may be subclinical or associated with two kinds of symptoms: those associated with the presence of undigested food within the intestinal lumen (fatty diarrhoea, flatulence, dyspeptic symptoms)⁹¹ and those associated with the loss of nutrients (mainly weight loss and fat-soluble vitamin deficit). The pancreas is involved in the digestion of proteins, carbohydrates, fat, and other nutrients, but pancreatic lipase is so essential for fat absorption that most of the clinical consequences of EPI are related to fat maldigestion. The extent of malabsorption depends on the original disease process and the type and extent of surgical resection.⁹² The main clinical manifestation of fat malabsorption is steatorrhea typically reported as an increase in bowel movements, particularly after fatty meals, with loose, greasy, foul-smelling voluminous stools.^{47,93} Steatorrhea, however, may be not present or present because of another cause. Postprandial abdominal pain and abdominal bloating may also be associated with EPI.⁴⁷

In patients with untreated EPI, potential additional complications such as weight loss, poor wound healing, vitamin deficiencies, osteomalacia, osteoporosis, and low-trauma fractures, electrolyte imbalance, increased adverse effects of oncological treatments, and lethargy can theoretically appear. One study compared pancreatic enzymes and placebo after surgery for chronic pancreatitis; four out of five patients receiving pancreatic enzymes gained weight but none of those six patients receiving placebo did.⁹⁰ Apart from weight loss, there are no specific studies demonstrating a different nutritional status in patients with or without EPI after pancreatic surgery.^{4,49}

Question 7

What Is the Optimal Method for the Diagnosis of EPI After Pancreatic Surgery?

Statement. PFT are of limited clinical value after pancreatic surgery as the prevalence of EPI is high and PFT are either difficult to

perform or have poor predictive values. In cases when objective evidence for EPI is needed, FFE may be considered as the gold standard. Human elastase-1 (FE1) is easy to perform, has a high sensitivity to detect steatorrhea but its specificity seems lower. The 13C-MTG may be an alternative method but further studies are needed. The absence of clinical symptoms of steatorrhea is an inaccurate method to rule out the existence of EPI.

Strength of the Recommendation and Quality of Evidence: 2B Strong Agreement (A: 35%; B: 40%; C: 22.5%; E: 2.5%)

Remarks. Currently FFE/CFA may be considered as a gold standard for EPI (see question 1). Unfortunately, this technique is cumbersome to perform: it requires a specific diet with a given amount of fat per day and stools from 3 days must be collected and processed. For these reasons, it would be very useful to have simpler PFTs like FE-1 and/or 13C-MTG but few studies have tried to validate them for the diagnosis of steatorrhea by means of FFE or CFA after pancreatic surgery.^{4,51} Halloran et al⁴ studied 40 operated patients for pancreatic cancer (37 PD and only three left pancreatectomies) by FE-1 and CFA. A comparison of FE-1 using a cut-off point of 200 microg/g for EPI against CFA showed a diagnostic accuracy of 70%, with a sensitivity of 91%, a specificity of 35%, a positive predictive value of 70%, and a negative predictive value of 71% for FE-1. There was no clear association between CFA and FE-1 levels. Overall, this study suggests the limited accuracy of FE-1 to diagnose EPI after pancreatic surgery. In another study Benini et al⁵¹ studied 40 operated patients (37 pylorus preserving PD, one Whipple procedure, and two total pancreatectomies) and 42 nonoperated patients with pancreatic diseases, and evaluated EPI by FE-1 compared with FFE. Sensitivity and specificity of FE-1 in operated patients to detect steatorrhea were as follows: 100% and 83.3% for FE-1 < 200 mcg/g; 100% and 100% for FE-1 < 100 mcg/g and 61.8%, respectively, and 100% for FE-1 < 15 mcg/g. The cut-off for FE-1 in the diagnosis of EPI was considerably higher in operated compared with nonoperated patients. Another conclusion of this study is that the relationship between both tests is not linear but logarithmic. The rate of increase of 24 hours fecal fat output with decreasing FE-1 levels is not constant but depends on FE-1 values, with rates much higher when FE-1 values are low. The information regarding the correlation between FE-1 and FFE in left pancreatectomy is lacking. Nakamura et al⁹⁴ investigated the usefulness of 13C-MTG compared with FE-1 concentration, but they used clinical steatorrhea as a gold standard. According to their results, the

13C-MTG might be more useful than the FE-1 for the diagnosis of EPI after pancreatic surgery because of its higher accuracy, which could be explained by the fact that fecal water content influences the fecal enzyme concentration, resulting in falsely decreased FE-1 levels. The advantages and disadvantages of the different available PFT are shown in Table 3.

To sum-up we need more studies to validate the use of FE-1 (which was associated with a poor correlation with FFE in two studies and poor accuracy for the diagnosis of steatorrhea in one of them) and 13C-MTG in surgical patients. In this scenario, the diagnosis of EPI may be assumed in patients with symptoms suggesting malabsorption. On the other hand, the absence of clinical symptoms of steatorrhea is not an accurate method to exclude the existence of EPI,^{2,12} and therefore PFT have a role in the diagnosis of EPI in asymptomatic patients.

Question 8

When Should EPI Be Treated? Statement

Pancreatic enzyme replacement therapy should start once EPI is diagnosed or when there is a high clinical suspicion of EPI.

Strength of the Recommendation and Quality of Evidence: 2B Strong Agreement (A: 72.5%; B: 25%; C: 2.5%)

Remarks. There is a paucity of high quality trials specifically designed to assess when to treat EPI in patients with previous pancreatic surgery. Most recommendations come from expert opinion or guidelines from medical societies.^{9,47,95-98}

The incidence of EPI associated with different surgical techniques, its clinical consequences, and diagnosis have been addressed in specific questions in this review. As a summary, deterioration of pancreatic function frequently occurs after pancreatic surgery; this condition is associated with relevant consequences. In patients with pancreatic surgery and EPI, pancreatic enzyme replacement therapy improves the CFA, the coefficient of nitrogen absorption, and reduces flatulence, diarrhea, and abdominal pain,^{90,91,99,100} and therefore EPI should be treated as soon as it is diagnosed. However, the task of establishing the diagnosis of EPI in patients with previous pancreatic surgery does not have a straightforward approach.⁵¹ To overcome this limitation in patients with a high clinical suspicion of EPI, its diagnosis may be accepted after an empiric therapeutic trial showing that symptoms, nutritional markers or body weight improve after pancreatic enzyme replacement therapy.

TABLE 3. Advantages and Disadvantages of the Main Different Available Pancreatic Function Tests

Pancreatic Function Test	Advantages	Disadvantages
Fecal fat excretion/ Coefficient of Fat Absorption	Clinically relevant	Very cumbersome and difficult to perform
Fecal elastase-1	It detects other causes of maldigestion Useful for monitoring response to treatment Very easy to perform Widely available	Not widely available It does not detect other causes of maldigestion Not useful for monitoring response to treatment Low correlation with fecal fat excretion in operated patients
13C-labeled mixed triglyceride breath test	Theoretically it detects other causes of maldigestion Probably useful for monitoring response to treatment	Time-consuming Not properly validated Expensive Scarcely available

Question 9**How Should EPI be Treated and How Should Follow-up Be Performed?**

Statement A. EPI after pancreatic surgery should be treated with pancreatic enzyme replacement therapy with pancreatin in form of enteric-coated minimicrospheres. Enzyme doses of 72,000–75,000 Ph.U. of lipase with main meals and 36,000–50,000 Ph.U. with snacks have shown to be effective in terms of improvement in fat digestion.

Strength of the Recommendation and Quality of Evidence: 1A. Strong Agreement (A: 70%; B: 27.5%; D: 2.5%)

Statement B. Follow up should be based on symptoms and nutritional evaluation, including body weight and routine nutritional parameters in blood.

Strength of the Recommendation and Quality of Evidence: 2C. Strong Agreement (A: 70%; B: 27.5%; D: 2.5%)

Remarks. Treatment of EPI after any pancreatic surgical procedure should be based on oral pancreatic enzyme replacement therapy.^{91,99,101} Enzyme doses of 72,000–75,000 Ph.U. of lipase with main meals and 36,000–50,000 Ph.U. with snacks have shown to be effective in terms of improvement in fat digestion in RCTs.^{91,101} Only two double-blind RCTs evaluating pancreatic enzyme replacement therapy for EPI in patients after pancreatic surgery have been reported.^{91,101} An open-label long-term follow-up study was reported,⁹⁹ with the patients from the double-blind study previously published by Whitcomb et al⁹¹ In these two latter studies,^{91,99} results of operated patients are reported together with nonoperated patients with chronic pancreatitis, but the study from Seiler et al¹⁰¹ only addresses operated patients, which also includes data from open-label pancreatic enzyme replacement therapy administration for 1 year.

Compared with placebo, pancreatic enzyme replacement therapy with pancreatin in form of enteric-coated minimicrospheres is associated with a significant improvement of fat (CFA)^{91,101} and protein digestion (coefficient of nitrogen absorption)¹⁰¹ in patients after pancreatic resection for chronic pancreatitis or pancreatic cancer. In addition, pancreatic enzyme replacement therapy is associated with a significant weight gain and reduced stool frequency.^{99,101}

No study has been published which specifically focused on dietary advice for patients after pancreatic surgery, it seems reasonable that a normal healthy diet should be generally recommended if tolerated.

No study has been found to answer the question about the follow up of EPI in patients after pancreatic surgery. In our opinion, follow up should be based on symptoms and nutritional evaluation, including body weight and some routine nutritional parameters in blood (eg, albumin, fat-soluble vitamins). Frequency of visits should be defined depending on the clinical and nutritional status of patients. Once the therapy has been optimized and the clinical and nutritional evaluation is normal, further follow up should probably be on-demand.

Question 10**What Is the Quality of Life in Operated Patients With EPI?**

Statement. Exocrine pancreatic insufficiency is a relevant prognostic factor related to impaired quality of life in patients who undergo pancreatic surgery.

Strength of the Recommendation and Quality of Evidence: 1B Strong Agreement (A: 72.5%; B: 25%; C: 2.5%)

Remarks. Quality of life deteriorates in patients who develop EPI after pancreatic resection.^{101,102} In addition, the development of postoperative EPI is a relevant prognostic factor, significantly affecting the postoperative quality of life.⁴¹ Patients undergoing surgery caused by pancreatic cancer with EPI score lower on quality of life and functional scores.⁴ Long-term follow-up survivors are generally satisfied with their quality of life, but bowel function, steatorrhea, need for treatment of diarrhea, or need for pancreatic enzyme replacement therapy and food intolerance may impair quality of life.^{103–105} Patients with benign pancreatic tumors had higher quality of life values at all time points compared with patients with pancreatitis and cancer; however, it is interesting to point out that quality of life in this group did not reach normal values for the healthy population even late after surgery, although these patients underwent curative therapy and did not suffer per se a chronic pancreatic disease.⁴¹ This is probably because of a higher rate of postoperative EPI.^{41,106} Total pancreatectomy (TP) has a deep influence on short- and long-term changes in the quality of life and EPI appears to be an important factor^{41,107} because it especially affects symptom scales.¹⁰⁸ In acute pancreatitis, patients with long-term survival after surgical treatment for infected pancreatic necrosis have a quality of life comparable with that of the normal population.¹⁷ In patients with chronic pancreatitis requiring surgery, quality of life improves significantly both in the short and long term.⁴¹ Although the number of patients with exocrine insufficiency is very high in CP, in some studies such complication does not seem to have relevance in the overall reported quality of life.^{23,28,109} Finally, in operated patients, regardless of the disease requiring pancreatic resection, the type of reconstruction technique does not affect their well being,¹¹⁰ and also among different types of pancreatic head resection, the majority of functional and symptom scales revealed a better quality of life and less steatorrhea in duodenum-preserving pancreatic head resection.^{36,111}

CONCLUSIONS

Pancreatic surgery is still a great challenge as it is frequently associated with immediate surgical complications and long-term sequelae. EPI is a frequent but under-recognized and under-treated complication of pancreatic surgery. The lack of awareness and information regarding the frequency, diagnostic methods, and recommended therapy prompted the Spanish Association of Pancreatology to design the present systematic review. EPI is commonly observed after pancreatic surgery, it is clinically relevant and affects quality of life; thus, it should be investigated, treated, and followed-up appropriately. The most important limitation of the literature and the origin of much of the confusion on this topic is that the diagnosis of EPI depends on the definition and the method used for measuring EPI and there is a lack of studies trying to validate PFT with a proper gold standard in operated patients. Therefore, further research is needed to look for better and simpler diagnostic tools.

ACKNOWLEDGMENT

The authors would like to thank Ms. Landy Menzies for language assistance in revising the English of the article. Professor John Neoptolemos is The Owen and Ellen Evans Chair of Surgery, University of Liverpool and is a National Institutes of Health (NIHR) Senior Investigator.

REFERENCES

1. Working Group IAPAAPAG. IAP/APA evidence-based guidelines for the management of acute pancreatitis. *Pancreatol*. 2013;13:e1–e15.

2. Martinez J, Abad-Gonzalez A, Aparicio JR, et al. The Spanish Pancreatic Club recommendations for the diagnosis and treatment of chronic pancreatitis: part 1 (diagnosis). *Pancreatol.* 2013;13:8–17.
3. DiMagno EP, Go VL, Summerskill WH. Relations between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency. *N Engl J Med.* 1973;288:813–815.
4. Halloran CM, Cox TF, Chauhan S, et al. Partial pancreatic resection for pancreatic malignancy is associated with sustained pancreatic exocrine failure and reduced quality of life: a prospective study. *Pancreatol.* 2011;11:535–545.
5. Tran TC, van 't Hof G, Kazemier G, et al. Pancreatic fibrosis correlates with exocrine pancreatic insufficiency after pancreatoduodenectomy. *Digestive Surg.* 2008;25:311–318.
6. Yuasa Y, Murakami Y, Nakamura H, et al. Histological loss of pancreatic exocrine cells correlates with pancreatic exocrine function after pancreatic surgery. *Pancreas.* 2012;41:928–933.
7. Eddes EH, Masclee AA, Gielkens HA, et al. Cholecystokinin secretion in patients with chronic pancreatitis and after different types of pancreatic surgery. *Pancreas.* 1999;19:119–125.
8. Malfertheiner P, Buchler M, Glasbrenner B, et al. Adaptive changes of the exocrine pancreas and plasma cholecystokinin release following subtotal gastric resection in rats. *Digestion.* 1987;38:142–151.
9. Tran TC, van Lanschot JJ, Bruno MJ, et al. Functional changes after pancreatoduodenectomy: diagnosis and treatment. *Pancreatol.* 2009;9:729–737.
10. Gupta R, Wig JD, Bhasin DK, et al. Severe acute pancreatitis: the life after. *J Gastrointest Surg.* 2009;13:1328–1336.
11. Sabater L, Pareja E, Aparisi L, et al. Pancreatic function after severe acute biliary pancreatitis: the role of necrosectomy. *Pancreas.* 2004;28:65–68.
12. Reddy MS, Singh S, Singh R, et al. Morphological and functional outcome after pancreatic necrosectomy and lesser sac lavage for necrotizing pancreatitis. *Indian J Gastroenterol.* 2007;26:217–220.
13. Tsiotos GG, Luque-de Leon E, Sarr MG. Long-term outcome of necrotizing pancreatitis treated by necrosectomy. *Br J Surg.* 1998;85:1650–1653.
14. Bavare C, Prabhu R, Supe A. Early morphological and functional changes in pancreas following necrosectomy for acute severe necrotizing pancreatitis. *Indian J Gastroenterol.* 2004;23:203–205.
15. Angelini G, Pederzoli P, Caliani S, et al. Long-term outcome of acute necrohemorrhagic pancreatitis. A 4-year follow-up. *Digestion.* 1984;30:131–137.
16. Seligson U, Ihre T, Lundh G. Prognosis in acute haemorrhagic, necrotizing pancreatitis. *Acta Chirurgica Scand.* 1982;148:423–429.
17. Reszetow J, Hac S, Dobrowolski S, et al. Biliary versus alcohol-related infected pancreatic necrosis: similarities and differences in the follow-up. *Pancreas.* 2007;35:267–272.
18. Bozkurt T, Maroske D, Adler G. Exocrine pancreatic function after recovery from necrotizing pancreatitis. *Hepato-gastroenterology.* 1995;42:55–58.
19. Beattie GC, Mason J, Swan D, et al. Outcome of necrosectomy in acute pancreatitis: the case for continued vigilance. *Scand J Gastroenterol.* 2002;37:1449–1453.
20. Connor S, Alexakis N, Raraty MG, et al. Early and late complications after pancreatic necrosectomy. *Surgery.* 2005;137:499–505.
21. van Santvoort HC, Besselink MG, Bakker OJ, et al. A step-up approach or open necrosectomy for necrotizing pancreatitis. *New Engl J Med.* 2010;362:1491–1502.
22. Jalleh RP, Williamson RC. Pancreatic exocrine and endocrine function after operations for chronic pancreatitis. *Ann Surg.* 1992;216:656–662.
23. van der Gaag NA, van Gulik TM, Busch OR, et al. Functional and medical outcomes after tailored surgery for pain due to chronic pancreatitis. *Ann Surg.* 2012;255:763–770.
24. Schnelldorfer T, Lewin DN, Adams DB. Operative management of chronic pancreatitis: long-term results in 372 patients. *J Am Coll Surg.* 2007;204:1039–1045.
25. Liu BN, Zhang TP, Zhao YP, et al. Pancreatic duct stones in patients with chronic pancreatitis: surgical outcomes. *HBPD Int.* 2010;9:423–427.
26. Chiang KC, Yeh CN, Hsu JT, et al. Pancreaticoduodenectomy versus Frey's procedure for chronic pancreatitis: preliminary data on outcome and pancreatic function. *Surgery Today.* 2007;37:961–966.
27. Hildebrand P, Dudertadt S, Czymek R, et al. Different surgical strategies for chronic pancreatitis significantly improve long-term outcome: a comparative single center study. *Eur J Med Res.* 2010;15:351–356.
28. Bachmann K, Tomkoetter L, Kutup A, et al. Is the Whipple procedure harmful for long-term outcome in treatment of chronic pancreatitis? 15-years follow-up comparing the outcome after pylorus-preserving pancreatoduodenectomy and Frey procedure in chronic pancreatitis. *Ann Surg.* 2013;258:815–820.
29. Witzigmann H, Max D, Uhlmann D, et al. Outcome after duodenum-preserving pancreatic head resection is improved compared with classic Whipple procedure in the treatment of chronic pancreatitis. *Surgery.* 2003;134:53–62.
30. Farkas G, Leindler L, Daroczi M, et al. Prospective randomised comparison of organ-preserving pancreatic head resection with pylorus-preserving pancreaticoduodenectomy. *Langenbecks Arch Surg.* 2006;391:338–342.
31. Muller MW, Friess H, Martin DJ, et al. Long-term follow-up of a randomized clinical trial comparing Beger with pylorus-preserving Whipple procedure for chronic pancreatitis. *Br J Surg.* 2008;95:350–356.
32. Diener MK, Rahbari NN, Fischer L, et al. Duodenum-preserving pancreatic head resection versus pancreatoduodenectomy for surgical treatment of chronic pancreatitis: a systematic review and meta-analysis. *Ann Surg.* 2008;247:950–961.
33. McClaine RJ, Lowy AM, Matthews JB, et al. A comparison of pancreaticoduodenectomy and duodenum-preserving head resection for the treatment of chronic pancreatitis. *HPBV 11.* 2009;677–683.
34. Keck T, Adam U, Makowiec F, et al. Short- and long-term results of duodenum preservation versus resection for the management of chronic pancreatitis: a prospective, randomized study. *Surgery.* 2012;152:S95–S102.
35. Lu WP, Shi Q, Zhang WZ, et al. A meta-analysis of the long-term effects of chronic pancreatitis surgical treatments: duodenum-preserving pancreatic head resection versus pancreatoduodenectomy. *Chinese Med J.* 2013;126:147–153.
36. Zheng Z, Xiang G, Tan C, et al. Pancreaticoduodenectomy versus duodenum-preserving pancreatic head resection for the treatment of chronic pancreatitis. *Pancreas.* 2012;41:147–152.
37. Strate T, Taherpour Z, Bloechle C, et al. Long-term follow-up of a randomized trial comparing the beger and frey procedures for patients suffering from chronic pancreatitis. *Ann Surg.* 2005;241:591–598.
38. Keck T, Wellner UF, Riediger H, et al. Long-term outcome after 92 duodenum-preserving pancreatic head resections for chronic pancreatitis: comparison of Beger and Frey procedures. *J Gastrointest Surg.* 2010;14:549–556.
39. Frey CF, Mayer KL. Comparison of local resection of the head of the pancreas combined with longitudinal pancreaticojejunostomy (frey procedure) and duodenum-preserving resection of the pancreatic head (beger procedure). *World J surg.* 2003;27:1217–1230.
40. Riediger H, Adam U, Fischer E, et al. Long-term outcome after resection for chronic pancreatitis in 224 patients. *J Gastrointest Surg.* 2007;11:949–959.
41. Belyaev O, Herzog T, Chromik AM, et al. Early and late postoperative changes in the quality of life after pancreatic surgery. *Langenbecks Arch Surg.* 2013;398:547–555.
42. Ruckert F, Distler M, Hoffmann S, et al. Quality of life in patients after pancreaticoduodenectomy for chronic pancreatitis. *J Gastrointest Surg.* 2011;15:1143–1150.
43. Stapleton GN, Williamson RC. Proximal pancreatoduodenectomy for chronic pancreatitis. *Br J Surg.* 1996;83:1433–1440.
44. Sakorafas GH, Farnell MB, Nagorney DM, et al. Pancreatoduodenectomy for chronic pancreatitis: long-term results in 105 patients. *Arch Surg.* 2000;135:517–523.
45. Hutchins RR, Hart RS, Pacifico M, et al. Long-term results of distal pancreatectomy for chronic pancreatitis in 90 patients. *Ann Surg.* 2002;236:612–618.
46. Izbicki JR, Bloechle C, Broering DC, et al. Extended drainage versus resection in surgery for chronic pancreatitis: a prospective randomized trial comparing the longitudinal pancreaticojejunostomy combined with local pancreatic head excision with the pylorus-preserving pancreatoduodenectomy. *Ann Surg.* 1998;228:771–779.
47. Pezzilli R, Andriulli A, Bassi C, et al. Exocrine pancreatic insufficiency in adults: a shared position statement of the Italian association for the study of the pancreas. *World J Gastroenterol.* 2013;19:7930–7946.
48. Dominguez-Munoz JE. Pancreatic enzyme replacement therapy: exocrine pancreatic insufficiency after gastrointestinal surgery. *HPB.* 2009;11:3–6.
49. Sikkens EC, Cahen DL, de Wit J, et al. Prospective assessment of the influence of pancreatic cancer resection on exocrine pancreatic function. *Br J Surg.* 2014;101:109–113.
50. van der Gaag NA, Berkhemer OA, Sprangers MA, et al. Quality of life and functional outcome after resection of pancreatic cystic neoplasm. *Pancreas.* 2014;43:755–761.

51. Benini L, Amodio A, Campagnola P, et al. Fecal elastase-1 is useful in the detection of steatorrhea in patients with pancreatic diseases but not after pancreatic resection. *Pancreatology*. 2013;13:38–42.
52. Bock EA, Hurtuk MG, Shoup M, et al. Late complications after pancreaticoduodenectomy with pancreaticogastrostomy. *J Gastrointest Surg*. 2012;16:914–919.
53. Cataldegirmen G, Schneider CG, Bogoevski D, et al. Extended central pancreatic resection as an alternative for extended left or extended right resection for appropriate pancreatic neoplasms. *Surgery*. 2010;147:331–338.
54. Nakamura H, Murakami Y, Uemura K, et al. Predictive factors for exocrine pancreatic insufficiency after pancreatoduodenectomy with pancreaticogastrostomy. *J Gastrointest Surg*. 2009;13:1321–1327.
55. Falconi M, Mantovani W, Crippa S, et al. Pancreatic insufficiency after different resections for benign tumours. *Br J Surg*. 2008;95:85–91.
56. Fang WL, Su CH, Shyr YM, et al. Functional and morphological changes in pancreatic remnant after pancreaticoduodenectomy. *Pancreas*. 2007;35:361–365.
57. Nordback I, Parviainen M, Piironen A, et al. Obstructed pancreaticojejunostomy partly explains exocrine insufficiency after pancreatic head resection. *Scand J Gastroenterol*. 2007;42:263–270.
58. Matsumoto J, Traverso LW. Exocrine function following the whipple operation as assessed by stool elastase. *J Gastrointest Surg*. 2006;10:1225–1229.
59. Rault A, Sa Cunha A, Klopfenstein D, et al. Pancreaticojejunostomy is preferable to pancreaticogastrostomy after pancreaticoduodenectomy for long-term outcomes of pancreatic exocrine function. *J Am Coll Surg*. 2005;201:239–244.
60. Pessaux P, Aube C, Lebigot J, et al. Permeability and functionality of pancreaticogastrostomy after pancreaticoduodenectomy with dynamic magnetic resonance pancreatography after secretin stimulation. *J Am Coll Surg*. 2002;194:454–462.
61. Jang JY, Kim SW, Park SJ, et al. Comparison of the functional outcome after pylorus-preserving pancreatoduodenectomy: pancreaticogastrostomy and pancreaticojejunostomy. *World J Surg*. 2002;26:366–371.
62. Lemaire E, O'Toole D, Sauvanet A, et al. Functional and morphological changes in the pancreatic remnant following pancreaticoduodenectomy with pancreaticogastric anastomosis. *Br J Surg*. 2000;87:434–438.
63. Sato N, Yamaguchi K, Chijiwa K, et al. Duct-parenchymal ratio predicts exocrine pancreatic function after pancreatoduodenectomy and distal pancreatectomy. *Am J Surg*. 1998;176:270–273.
64. Sato N, Yamaguchi K, Yokohata K, et al. Short-term and long-term pancreatic exocrine and endocrine functions after pancreatectomy. *Dig Dis Sci*. 1998;43:2616–2621.
65. Fujino Y, Suzuki Y, Matsumoto I, et al. Long-term assessments after pancreaticoduodenectomy with pancreatic duct invagination anastomosis. *Surgery Today*. 2007;37:860–866.
66. van Berge Henegouwen MI, Moojen TM, van Gulik TM, et al. Postoperative weight gain after standard Whipple's procedure versus pylorus-preserving pancreatoduodenectomy: the influence of tumour status. *Br J Surg*. 1998;85:922–926.
67. Hirono S, Murakami Y, Tani M, et al. Identification of risk factors for pancreatic exocrine insufficiency after pancreaticoduodenectomy using a 13C-labeled mixed triglyceride breath test. *World J Surg*. 2015;39:516–525.
68. Xu SB, Zhu YP, Zhou W, et al. Patients get more long-term benefit from central pancreatectomy than distal resection: a meta-analysis. *Eur J Surg Oncol*. 2013;39:567–574.
69. Speicher JE, Traverso LW. Pancreatic exocrine function is preserved after distal pancreatectomy. *J Gastrointest Surg*. 2010;14:1006–1011.
70. Muller MW, Friess H, Kleeff J, et al. Middle segmental pancreatic resection: an option to treat benign pancreatic body lesions. *Ann Surg*. 2006;244:909–918.
71. Hirono S, Tani M, Kawai M, et al. A central pancreatectomy for benign or low-grade malignant neoplasms. *J Gastrointest Surg*. 2009;13:1659–1665.
72. Rotman N, Sastre B, Fagniez PL. Medial pancreatectomy for tumors of the neck of the pancreas. *Surgery*. 1993;113:532–535.
73. Iacono C, Bortolasi L, Serio G. Indications and technique of central pancreatectomy—early and late results. *Langenbeck Arch Surg*. 2005;390:266–271.
74. Sperti C, Pasquali C, Ferronato A, et al. Median pancreatectomy for tumors of the neck and body of the pancreas. *J Am Coll Surg*. 2000;190:711–716.
75. Ikeda S, Matsumoto S, Maeshiro K, et al. Segmental pancreatectomy for the diagnosis and treatment of small lesions in the neck or body of the pancreas. *Hepatogastroenterology*. 1995;42:730–733.
76. Yasuda H, Takada T, Toyota N, et al. Limited pancreatectomy: significance of postoperative maintenance of pancreatic exocrine function. *J Hepatobiliary Pancreat Surg*. 2000;7:466–472.
77. Shibata S, Sato T, Andoh H, et al. Outcomes and indications of segmental pancreatectomy. Comparison with distal pancreatectomy. *Digestive Surg*. 2004;21:48–53.
78. Sudo T, Murakami Y, Uemura K, et al. Middle J Surg Oncol; 2010;101:61–65.
79. Warshaw AL, Rattner DW, Fernandez-del Castillo C, et al. Middle segment pancreatectomy: a novel technique for conserving pancreatic tissue. *Arch Surg*. 1998;133:327–331.
80. de Claviere G, Paye F, Fteriche S, et al. Medial pancreatectomy: results of a series of 11 patients. *Ann Surg*. 2002;127:48–54.
81. Balzano G, Zerbi A, Veronesi P, et al. Surgical treatment of benign and borderline neoplasms of the pancreatic body. *Digestive Surg*. 2003;20:506–510.
82. Efron DT, Lillemoe KD, Cameron JL, et al. Central pancreatectomy with pancreaticogastrostomy for benign pancreatic pathology. *J Gastrointest Surg*. 2004;8:532–538.
83. Roggin KK, Rudloff U, Blumgart LH, et al. Central pancreatectomy revisited. *J Gastrointest Surg*. 2006;10:804–812.
84. Allendorf JD, Schrope BA, Lauerman MH, et al. Postoperative glycemic control after central pancreatectomy for mid-gland lesions. *World J Surg*. 2007;31:164–168.
85. Huang H, Dong X, Gao SL, et al. Conservative resection for benign tumors of the proximal pancreas. *World J Surg*. 2009;15:4044–4048.
86. LaFemina J, Vagefi PA, Warshaw AL, et al. Transgastric pancreaticogastric anastomosis: an alternative operative approach for middle pancreatectomy. *Arch Surg*. 2010;145:476–481.
87. Lee SE, Jang JY, Hwang DW, et al. Clinical efficacy of organ-preserving pancreatectomy for benign or low-grade malignant potential lesion. *J Korean Med Sci*. 2010;25:97–103.
88. Chen XM, Zhang Y, Sun DL. Laparoscopic central pancreatectomy for solid pseudopapillary tumors of the pancreas: our experience with ten cases. *World J Surg Oncol*. 2014;12:312.
89. Iacono C, Verlato G, Ruzzenente A, et al. Systematic review of central pancreatectomy and meta-analysis of central versus distal pancreatectomy. *Br J Surg*. 2013;100:873–885.
90. Van Hoozen CM, Peeke PG, Taubeneck M, et al. Efficacy of enzyme supplementation after surgery for chronic pancreatitis. *Pancreas*. 1997;14:174–180.
91. Whitcomb DC, Lehman GA, Vasileva G, et al. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial. *Am J Gastroenterol*. 2010;105:2276–2286.
92. Ghaneh P, Neoptolemos JP. Exocrine pancreatic function following pancreatectomy. *Ann N Y Acad Sci*. 1999;880:308–318.
93. Forsmark CE. Chronic pancreatitis and malabsorption. *Am J Gastroenterol*. 2004;99:1355–1357.
94. Nakamura H, Morifuji M, Murakami Y, et al. Usefulness of a 13C-labeled mixed triglyceride breath test for assessing pancreatic exocrine function after pancreatic surgery. *Surgery*. 2009;145:168–175.
95. Sikkens EC, Cahen DL, van Eijck C, et al. The daily practice of pancreatic enzyme replacement therapy after pancreatic surgery: a northern European survey: enzyme replacement after surgery. *J Gastrointest Surg*. 2012;16:1487–1492.
96. Keim V, Klar E, Poll M, et al. Postoperative care following pancreatic surgery: surveillance and treatment. *Deutsches Arzteblatt International*. 2009;106:789–794.
97. DiMagno MJ, DiMagno EP. Chronic pancreatitis. *Curr Opin Gastroenterol*. 2012;28:523–531.
98. Friess H, Michalski CW. Diagnosing exocrine pancreatic insufficiency after surgery: when and which patients to treat. *HPB*. 2009;11(suppl 3):7–10.
99. Gubergrits N, Malecka-Panas E, Lehman GA, et al. A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery. *Aliment Pharmacol Ther*. 2011;33:1152–1161.
100. Bruno MJ, Borm JJ, Hoek FJ, et al. Comparative effects of enteric-coated pancreatin microsphere therapy after conventional and pylorus-preserving pancreatoduodenectomy. *Br J Surg*. 1997;84:952–956.
101. Seiler CM, Izbicki J, Varga-Szabo L, et al. Randomised clinical trial: a 1-week, double-blind, placebo-controlled study of pancreatin 25 000 Ph. Eur. minimicrospheres (Creon 25000 MMS) for pancreatic exocrine insufficiency after pancreatic surgery, with a 1-year open-label extension. *Aliment Pharmacol Ther*. 2013;37:691–702.

102. Pezzilli R, Falconi M, Zerbi A, et al. Clinical and patient-reported outcomes after pancreatoduodenectomy for different diseases: a follow-up study. *Pancreas*. 2011;40:938–945.
103. Yu HH, Yang TM, Shan YS, et al. Zinc deficiency in patients undergoing pancreatoduodenectomy for periampullary tumors is associated with pancreatic exocrine insufficiency. *World J Surg*. 2011;35:2110–2117.
104. Armstrong T, Walters E, Varshney S, et al. Deficiencies of micronutrients, altered bowel function, and quality of life during late follow-up after pancreaticoduodenectomy for malignancy. *Pancreatology*. 2002;2:528–534.
105. Le Page S, Caputo S, Kwiatkowski F, et al. Functional outcome and quality of life after pancreaticoduodenectomy. *Journal de chirurgie*. 2008;145:32–36.
106. Nguyen TC, Sohn TA, Cameron JL, et al. Standard vs. radical pancreaticoduodenectomy for periampullary adenocarcinoma: a prospective, randomized trial evaluating quality of life in pancreaticoduodenectomy survivors. *J Gastrointest Surg*. 2003;7:1–9.
107. Billings B J, Christein F, Harmsen W S, et al. Quality-of-life after total pancreatectomy: is it really that bad on long-term follow-up? *J Gastrointest Surg*. 2005;9:1059–1066.
108. Casadei R, Ricci C, Monari F, et al. Clinical outcome of patients who underwent total pancreatectomy. *Pancreas*. 2010;39:546–547.
109. Strate T, Bachmann K, Busch P, et al. Resection vs drainage in treatment of chronic pancreatitis: long-term results of a randomized trial. *Gastroenterology*. 2008;134:1406–1411.
110. Pezzilli R, Falconi M, Zerbi A, et al. Different reconstruction techniques after pancreatoduodenectomy do not affect clinical and patient reported outcomes. *Adv Med Sci*. 2014;59:151–155.
111. Chen HM, Jan YY, Chao TC, et al. Pancreatoduodenectomy for chronic pancreatitis with an inflammatory mass of pancreatic head: preoperative and postoperative functional assessment. *Hepato-gastroenterology*. 2003;50:2213–2217.